Found: 237
Select item for more details and to access through your institution.
653 - Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema: pooled results of the phase 3 DELTA-1 and -2 trials.
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.032
- By:
- Publication type:
- Article
655 - Long-term safety and efficacy of delgocitinib cream for up to 36 weeks in adults with chronic hand eczema: results of the phase 3 open-label extension DELTA-3 trial.
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.034
- By:
- Publication type:
- Article
649 - Safety of tralokinumab for the treatment of atopic dermatitis in patients with up to 4.5 years of treatment: an updated integrated analysis of eight clinical trials.
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.028
- By:
- Publication type:
- Article
693 - Efficacy and safety of orismilast, a potent PDE4B/D inhibitor, in adults with moderate-to-severe atopic dermatitis: a phase 2b randomized, double-blind, placebo-controlled clinical trial (ADESOS).
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.067
- By:
- Publication type:
- Article
619 - Lebrikizumab improves signs and symptoms of moderate-to-severe atopic dermatitis in patients not adequately controlled or non-eligible for cyclosporine: a placebo-controlled, randomized phase 3 clinical study (ADvantage).
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.005
- By:
- Publication type:
- Article
680 - Efficacy of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis by age of onset: analysis of two phase 3 clinical trials.
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.054
- By:
- Publication type:
- Article
Certolizumab Pegol for the Treatment of Plaque Psoriasis in Routine Clinical Practice: One-Year Results from the CIMREAL Study.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 8, p. 2077, doi. 10.1007/s13555-024-01210-3
- By:
- Publication type:
- Article
Deucravacitinib in moderate‐to‐severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO‐1 and PSO‐2).
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2024, v. 38, n. 8, p. 1543, doi. 10.1111/jdv.19925
- By:
- Publication type:
- Article
The use of serum methotrexate level as an assessment of biochemical drug adherence in psoriasis.
- Published in:
- British Journal of Dermatology, 2024, v. 190, n. 6, p. 927, doi. 10.1093/bjd/ljae096
- By:
- Publication type:
- Article
O05 Single-cell transcriptomic signature of paradoxical eczema in patients with psoriasis treated with biologics.
- Published in:
- British Journal of Dermatology, 2024, v. 190, n. 6, p. e70, doi. 10.1093/bjd/ljae105.005
- By:
- Publication type:
- Article
Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison.
- Published in:
- Rheumatology & Therapy, 2024, v. 11, n. 3, p. 817, doi. 10.1007/s40744-024-00652-7
- By:
- Publication type:
- Article
Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison.
- Published in:
- Rheumatology & Therapy, 2024, v. 11, n. 3, p. 829, doi. 10.1007/s40744-024-00659-0
- By:
- Publication type:
- Article
Clinical course, treatment and management of generalised pustular psoriasis from a United Kingdom extension of a global Delphi panel.
- Published in:
- Skin Health & Disease, 2024, v. 4, n. 3, p. 1, doi. 10.1002/ski2.359
- By:
- Publication type:
- Article
Sewage Derived Microplastic and Anthropogenic Fibre Retention by Integrated Constructed Wetlands.
- Published in:
- Water, Air & Soil Pollution, 2024, v. 235, n. 6, p. 1, doi. 10.1007/s11270-024-07168-4
- By:
- Publication type:
- Article
OX40 in the Pathogenesis of Atopic Dermatitis—A New Therapeutic Target.
- Published in:
- American Journal of Clinical Dermatology, 2024, v. 25, n. 3, p. 447, doi. 10.1007/s40257-023-00838-9
- By:
- Publication type:
- Article
Correction to: OX40 in the Pathogenesis of Atopic Dermatitis—A New Therapeutic Target.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Functional Genomics and Insights into the Pathogenesis and Treatment of Psoriasis.
- Published in:
- Biomolecules (2218-273X), 2024, v. 14, n. 5, p. 548, doi. 10.3390/biom14050548
- By:
- Publication type:
- Article
Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials.
- Published in:
- British Journal of Dermatology, 2024, v. 190, n. 5, p. 668, doi. 10.1093/bjd/ljae014
- By:
- Publication type:
- Article
The association of age at psoriasis onset and HLA-C*06:02 with biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
- Published in:
- British Journal of Dermatology, 2024, v. 190, n. 5, p. 689, doi. 10.1093/bjd/ljad481
- By:
- Publication type:
- Article
Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials.
- Published in:
- British Journal of Dermatology, 2024, v. 190, n. 4, p. 477, doi. 10.1093/bjd/ljad429
- By:
- Publication type:
- Article
Discontinuation of anti-tumour necrosis factor alpha treatment owing to blood test abnormalities, and cost-effectiveness of alternate blood monitoring strategies.
- Published in:
- British Journal of Dermatology, 2024, v. 190, n. 4, p. 559, doi. 10.1093/bjd/ljad430
- By:
- Publication type:
- Article
Complete Hemifacial Paralysis Post-facelift: Making Sense of a Plastic Surgeon's Worst Nightmare.
- Published in:
- Aesthetic Surgery Journal, 2024, v. 44, n. 3, p. 256, doi. 10.1093/asj/sjad337
- By:
- Publication type:
- Article
Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for ≥ 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial.
- Published in:
- American Journal of Clinical Dermatology, 2024, v. 25, n. 2, p. 315, doi. 10.1007/s40257-023-00816-1
- By:
- Publication type:
- Article
Characteristics of 'super responders' and 'super nonresponders' to first biologic monotherapy for psoriasis: a nested case–control study.
- Published in:
- British Journal of Dermatology, 2024, v. 190, n. 3, p. 441, doi. 10.1093/bjd/ljad446
- By:
- Publication type:
- Article
Safety of tralokinumab for the treatment of atopic dermatitis in patients with up to 4.5 years of treatment: an updated integrated analysis of eight clinical trials.
- Published in:
- British Journal of Dermatology, 2024, v. 190, p. ii52, doi. 10.1093/bjd/ljad498.054
- By:
- Publication type:
- Article
Risk of Paradoxical Eczema in Patients Receiving Biologics for Psoriasis.
- Published in:
- JAMA Dermatology, 2024, v. 160, n. 1, p. 71, doi. 10.1001/jamadermatol.2023.4846
- By:
- Publication type:
- Article
Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative Review.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 12, p. 3031, doi. 10.1007/s13555-023-01054-3
- By:
- Publication type:
- Article
A Phase IIIb, Multicentre, Interventional, Randomised, Placebo-Controlled Clinical Trial Investigating the Efficacy and Safety of Guselkumab for the Treatment of Nonpustular Palmoplantar Psoriasis (G-PLUS).
- Published in:
- Dermatologic Therapy, 2023, p. 1, doi. 10.1155/2023/9967747
- By:
- Publication type:
- Article
Short-, Mid-, and Long-Term Efficacy of Deucravacitinib Versus Biologics and Nonbiologics for Plaque Psoriasis: A Network Meta-Analysis.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 11, p. 2839, doi. 10.1007/s13555-023-01034-7
- By:
- Publication type:
- Article
Commentary on: Facial Hypertrophy as a Complication of Weight Gain in Autologous Fat Graft Patients: Considerations and Recommendations.
- Published in:
- Aesthetic Surgery Journal, 2023, v. 43, n. 10, p. NP748, doi. 10.1093/asj/sjad215
- By:
- Publication type:
- Article
The risk of venous thromboembolism in atopic dermatitis: a matched cohort analysis in UK primary care.
- Published in:
- British Journal of Dermatology, 2023, v. 189, n. 4, p. 427, doi. 10.1093/bjd/ljad212
- By:
- Publication type:
- Article
Lifting the Anterior Midcheek and Nasolabial Fold: Introduction to the Melo Fat Pad Anatomy and Its Role in Longevity and Recurrence.
- Published in:
- Aesthetic Surgery Journal, 2023, v. 43, n. 9, p. 941, doi. 10.1093/asj/sjad126
- By:
- Publication type:
- Article
Effectiveness and survival of methotrexate versus adalimumab in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
- Published in:
- British Journal of Dermatology, 2023, v. 189, n. 3, p. 271, doi. 10.1093/bjd/ljad179
- By:
- Publication type:
- Article
Human Mast Cells Upregulate Cathepsin B, a Novel Marker of Itch in Psoriasis.
- Published in:
- Cells (2073-4409), 2023, v. 12, n. 17, p. 2177, doi. 10.3390/cells12172177
- By:
- Publication type:
- Article
Imsidolimab, an anti-interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis: results from the phase II GALLOP trial.
- Published in:
- British Journal of Dermatology, 2023, v. 189, n. 2, p. 161, doi. 10.1093/bjd/ljad083
- By:
- Publication type:
- Article
Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR).
- Published in:
- British Journal of Dermatology, 2023, v. 189, n. 1, p. 62, doi. 10.1093/bjd/ljad107
- By:
- Publication type:
- Article
O10 STAT3 activation in peripheral blood MAIT cells is a predictive biomarker of response to biologics targeting the IL-23/IL-17 axis.
- Published in:
- British Journal of Dermatology, 2023, v. 189, n. 1, p. e8, doi. 10.1093/bjd/ljad174.010
- By:
- Publication type:
- Article
O15 Using CRISPR-Cas9 to annotate the TYK2 pathway in psoriasis.
- Published in:
- British Journal of Dermatology, 2023, v. 189, n. 1, p. e10, doi. 10.1093/bjd/ljad174.015
- By:
- Publication type:
- Article
Biosimilars for the Treatment of Psoriasis: A Systematic Review of Clinical Trials and Observational Studies.
- Published in:
- JAMA Dermatology, 2023, v. 159, n. 7, p. 763, doi. 10.1001/jamadermatol.2023.1338
- By:
- Publication type:
- Article
395 Assessing imputation methods with the lebrikizumab clinical trial program.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. 1, doi. 10.1093/bjd/ljad162.020
- By:
- Publication type:
- Article
Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial.
- Published in:
- British Journal of Dermatology, 2023, v. 188, n. 6, p. 749, doi. 10.1093/bjd/ljad035
- By:
- Publication type:
- Article
Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for patients with moderate-to-severe psoriasis: a cohort study from BADBIR.
- Published in:
- British Journal of Dermatology, 2023, v. 188, n. 5, p. 618, doi. 10.1093/bjd/ljad004
- By:
- Publication type:
- Article
The effect of immunomodulators on seroconversion after BNT162b2 and AZD1222 vaccines in patients with immune-mediated inflammatory diseases: a prospective cohort study.
- Published in:
- British Journal of Dermatology, 2023, v. 188, n. 4, p. 542, doi. 10.1093/bjd/ljac109
- By:
- Publication type:
- Article
Oral orismilast: Efficacy and safety in moderate-to-severe psoriasis and development of modified release tablets.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2023, v. 37, n. 4, p. 711, doi. 10.1111/jdv.18812
- By:
- Publication type:
- Article
Pharmacology of orismilast, a potent and selective PDE4 inhibitor.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2023, v. 37, n. 4, p. 721, doi. 10.1111/jdv.18818
- By:
- Publication type:
- Article
Long-term stability of PASI <3 response to tildrakizumab: Pooled analyses from reSURFACE 1 and reSURFACE 2 phase 3 trials through 5years.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2023, v. 37, n. 4, p. e501, doi. 10.1111/jdv.18783
- By:
- Publication type:
- Article
Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials.
- Published in:
- British Journal of Dermatology, 2023, v. 188, n. 3, p. 330, doi. 10.1093/bjd/ljac089
- By:
- Publication type:
- Article
Association between psoriatic disease and lifestyle factors and comorbidities: cross-sectional analysis and Mendelian randomization.
- Published in:
- Rheumatology, 2023, v. 62, n. 3, p. 1272, doi. 10.1093/rheumatology/keac403
- By:
- Publication type:
- Article
309 Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate-to-severe atopic dermatitis: including adverse events of special interest.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. ii6, doi. 10.1093/bjd/ljac140.009
- By:
- Publication type:
- Article
Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials.
- Published in:
- British Journal of Dermatology, 2023, v. 188, n. 2, p. 198, doi. 10.1093/bjd/ljac040
- By:
- Publication type:
- Article